Table 3 Adverse events regarding CTCAE-3 in the XELIRI and FOLFIRI arms, data are shown as n (%)
XELIRI | FOLFIRI | ||
|---|---|---|---|
N = 41 | n = 46 | p | |
Hand-foot syndrome | |||
Grade 1 | 4 (10%) | 0 | 0.18 |
Grade 2 | 2 (5%) | 0 | 0.10 |
Grade 3 | 0 | 0 | - |
Diarrhoea | |||
Grade 1 | 1 (2%) | 4 (8%) | 0.18 |
Grade 2 | 4 (10%) | 7 (15%) | 0.37 |
Grade 3 | 1 (2%) | 2 (4%) | 0.56 |
Grade 4 | 2 (5%) | 1 (2%) | 0.56 |
Nausea | |||
Grade 1 | 3 (7%) | 8 (17%) | 0.13 |
Grade 2 | 6 (15%) | 1 (2%) | 0.06 |
Grade 3 | 0 | 0 | - |
Grade 4 | 0 | 0 | - |
Fatigue | |||
Grade 1 | 3 (7%) | 4 (9%) | 0.70 |
Grade 2 | 1 (2%) | 2 (4%) | 0.56 |
Grade 3 | 0 | 0 | - |
Grade 4 | 0 | 0 | - |
Neutropenia | |||
Grade 1 | 3 (7%) | 2 (4%) | 0.65 |
Grade 2 | 2 (5%) | 12 (26%) | 0.008 |
Grade 3 | 1 (2%) | 5 (11%) | 0.10 |
Grade 4 | 1 (2%) | 1 (2%) | 1.0 |
Thrombopenia of any grade | 0 | 0 | - |
Ischemic stroke | 0 | 1 (2%) | - |
Acute coronary syndrome | 1 (2%) | 2 (4%) | 0.56 |
Death* | 0 | 0 | - |